Pallas Capital Advisors jumped into the biotech game by purchasing $426,000 worth of Regeneron Pharmaceuticals shares during ...

The S&P 500 rebounded in May, but some stocks crashed on company-specific concerns. While one healthcare giant withdrew its ...

AI data centers need energy, and that’s what’s made the stock price of aptly-named NRG $NRG rise 88% in the past year ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ — Equity Insider News Commentary – The 2025 ASCO Annual Meeting has ...

EVGo shares, however, have doubled in the last 12 months and have gained nearly 60% in the last three months, far outpacing the S&P 500 index SPX in both time frames.

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

The stock’s decline was notably more severe than that of its partner, Sanofi (NASDAQ:SNY), which experienced a 6% drop. Bernstein SocGen analysts highlighted concerns about Regeneron’s ability ...

The founder of 23andMe has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, ...